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V o n  Recklinghausen neurofibromatosis (NF1), first 
described about 100 years ago, is one of the more fre- 
quent autosomal dominant mutations of humans 1,2. 
Although very little is known about the basic biology 
of the disease, genetic analysis has proceeded rapidly 
over  the past three years as a result of linkage analysis 
and physical mapping  techniques3. The purpose of 
this brief review is to describe these advances and to 
identify future challenges. Much of this information 
was recently discussed at a meeting of the 
International Consortium for NF Gene Cloning, spon- 
sored by the National Neurofibromatosis Foundation 
in February 1989, and we owe much gratitude to the 
Foundation and the participants in that consortium for 
permission to present this synthesis. 
Clinical features o f  NF1 
The diagnostic criteria for NF1, as recently enumer-  
ated by an NIH consensus conference 4, are listed in 
Table 1. A diagnosis is usually established by the find- 
ing of multiple caf~-au-lait spots and cutaneous neuro- 
fibromas (Fig. 1). Establishing a diagnosis in children 
may be difficult if multiple caf~-au-lait spots are not 
present, as the neurofibromas often do not make their 
appearance until adolescence. Besides the diagnostic 
criteria listed in Table 1, a variety of other com- 
plications can also bccur, ranging from milder difficul- 
ties such as itching and constipation to more serious 
problems such as seizures, learning disability, or even 
occasionally frank mental retardation, major ortho- 
pedic abnormalities, and the development  of 
malignancy, particularly neurofibrosarcoma or optic 
glioma. 
Genetics 
The landmark study of Crowe, Schull and Neel 1 in 
the 1950s demonstrated that NF1 is inherited in an 
autosomal dominant fashion. Penetrance is extremely 
high if careful attention is paid to the diagnostic 
criteria listed in Table 1, and there are few examples 
of genuine nonexpressing individuals. However, vari- 
able expressivity is the rule in this disorder, with a dra- 
matic variation in severity between affected individ- 
uals. This variation is in general as great within a 
family as between families, indicating that it is not 
simply a result of genetic heterogeneity. The incidence 
of the disorder is about 1 in 3000 in all races that have 
been carefully examined 2. A remarkable feature is the 
high spontaneous mutation rate, with 40-50% of all 
cases representing spontaneous mutations. This leads 
to a calculated mutation rate of 10 -4 per allele per gen- 
eration, among the highest such rates reported for a 
locus in humans. This may have important im- 
plications for the structure of the NF1 locus. 
In the past there has been some clinical and gen- 
etic confusion between NF1 and a related disorder, 
bilateral acoustic neurofibromatosis (NF2). In NF2 a 
few caf6-au-lait spots may be present, and occasionally 
a small number  of peripheral neurofibromas will also 
appear. The hallmark of NF2, however, is the presence 
of bilateral acoustic neuromas of the eighth cranial 
nerve3, which appear  in more than 90% of individuals 
with this gene by age 30. Acoustic neuromas are 
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lion Recklinghausen neuroflbromatosis (NFI) is a common 
autosomal dominant disorder of humans. Linkage analysis 
has recently mapped the NFI gene to the proximal long 
arm of chromosome 17. The identification of two NFI 
patients with balanced translocations has now allowed the 
location of the gene to be narrowed to a few hundred 
kilobases of chromosome band 17qi1.2, using a 
combination of somatic cell hybrid technology, linking 
clones and pulsed fleld gel electrophoresis. 
extremely rare in NF1. Although occasional families 
have been reported in which individuals appear  to 
have features of both disorders, the successful map-  
ping of NF1 to chromosome 17 (Refs 5, 6) and NF2 to 
chromosome 22 (Ref. 7) provides conclusive proof  that 
these are different disorders. 
Linkage analysis o f  NF1 
The relatively high frequency of the disorder, 
coupled with its high penetrance and associated high 
diagnostic accuracy, made NF1 an attractive target for 
linkage analysis as soon as sufficient panels of poly- 
morphic markers emerged. This effort, initiated by sev- 
eral groups who  worked together to establish an 
exclusion map, resulted in the identification of defini- 
tive linkage to the pericentromeric region of chromo- 
some 17 in the late spring of 1987~, 6. At the time of 
writing, no families with classic NF1 have been identi- 
fied that do not show linkage to this region; therefore, 
it is likely that this disease represents mutation at a 
single locus. 
Over the past year and a half, a large number  of 
additional polymorphic markers have been generated 
T~m~. 1. Diagnost ic  c ~  for  NF1 
Two or more of the following: 
(1) ->6 Caf6-au-lait spots 
-> 1.5 cm in postpubertal individual 
>- 0.5 cm in prepubertal individual 
(2) -> 2 Neurofibromas of any type, or > 1 plexiform 
neurofibroma (a deeply placed, large and 
complex neurofibroma) 
(3) Freckling of the armpits or groin 
(4) Optic gtioma (tumor of the optic nerve) 
(5) -> 2 Lisch nodules (benign hamartomas of the 
iris) 
(6) A distinctive bony lesion 
- dysplasia of the sphenoid bone 
- dysplasia or thinning of long bone cortex 
(7) First degree relative with NFI 
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from chromosome 17, and these 
probes have been tested by the 
various groups involved in link- 
age analysis, in a productive 
collaborative effort sponsored by 
the National Neurofibromatosis 
Foundation. In a series of pub- 
lished reports, first in Genomics 
and then in the American 
Journal of Human Genetics, an 
intense genetic analysis of this 
disorder was carried out. The 
genetic mapping effort culminated 
in the multipoint linkage map 
shown in Fig. 2, which was con- 
structed by David Goldgar and 
colleagues from the collaborative 
group's eflbrtsS. This multipoint 
map represents the outcome of 
the study of 142 families with 
over 700 affected individuals, and 
a total of 13 838 genotypings. It is 
apparent from Fig. 2 that probes 
on either side of NF1 are now 
available within less than 5 cM of 
the gene, so that application of 
DNA technology to prenatal or 
presymptomatic diagnosis of this disease is now possible. 
This genetic analysis thus places NF1 on the proxi- 
mal long arm of chromosome 17. Initial surveys of this 
region revealed at least three candidate genes: two of 
these, the nerve growth factor receptor and the erbA1 
proto-oncogene, were quickly shown to map distal to 
NF1 by the identification of recombinant individuals<9: 
a third candidate gene, the erbB2 proto-oncogene 
(also sometimes called NE6'I HER2 or NGL), has not 
yet yielded a polymorphism and so could not be 
mapped genetically. Subsequent physical mapping 
experiments, however, have now also excluded this 
locus (see bek)w). 
S~TGn 
Typical appearance of the skin in an indi- 
vidual with NF1. A caf6-au-lait spot, a large 
neurofibroma, and several small neuro- 
fibromas are apparent. 
NF1 and balanced translocations 
As expected for an autosomal 
dominant disorder, cytogenetic 
analysis of patients with NF1 has 
in general been quite unreveal- 
ing. However, two unique 
patients have been identified who 
have NF1 in association with 
apparently balanced transloca- 
tions 1°,11 and these have played a 
critical role in fine mapping of 
the gene. 
This is perhaps an important 
lesson for reverse genetics of 
other diseases: the identification 
of such cytogenetic abnormalities. 
even if they represent only a rare 
mechanism of causation for a 
particular disease, can greatly 
accelerate the identification of the 
responsible region. Such cyto- 
genetic abnormalities have, for 
example, aided the identification 
of the Duchenne muscular dys- 
trophy 12, chronic granulomatous 
diseaseL3 retinoblastomal4 and 
sex determination loci is, and the 
absence of such abnormalities has hindered the rapid 
identification of the cystic fibrosis I(' and Huntington 
disease 17 loci. 
A diagram of the cytogenetic abnormalities 
identified in the two unique NF1 patients is shown in 
Fig. 3. In one situation > an apparently balanced 
translocation has occurred between lp34.3 anti 
17q11.2. In the other situationlL the translocation 
involves 17q11.2 and 22q11.2. The fact that one break- 
point in both instances inw)lves 17q11.2, precisely 
where the NF1 gene has been mapped by linkage 
analysis, is strong circumstantial evidence that these 
translocations are in fact causative rather than coinci- 
dental. 
/qG Iil 
Muttipoint linkage map of eM 
the NF1 region of chro- 
mosome 17 (from Ref. 8). 3.3 
The alpha satellite marker 
D17Z1 indicates the posi- 
tion of the cenm)mere. 5.5 
The order of markers 
shown is favored by at 2.4 
least 100:1 odds over 0.6 alternatives that involve 
interchanging a pair of 2.3 
adjacent markers. The 
genetic distances (in cen- 
timorgans) are sex-aver- 5.1 
aged; in this region of 
chromosome 17, as in 1.2 
much of the human 1.2 
genome, genetic distances 1.5 
are about two to three 2.1 
times greater in female 
meiosis than in male 
meiosis. 
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Mapping with somatic cell hybrids 
The convenient localization of the selectable marker 
thymidine kinase (TK) on distal 17q has greatly facili- 
tated the creation of a robust panel of somatic cell 
hybrids involving various segments of chromosome 
17. Such a panel is shown in Fig. 4, although this 
represents only a subset of the hybrids created by 
Ledbetter 11 and by Leach and Fournier >. Particularly 
noteworthy in Fig. 4 are the hybrids denoted DCR-1 
and NF13, which are respectively derived from the 
t(1;17) and t(17;22) patients. Thus, the endpoint of 
these two hybrids, which occur at the interface 
between the regions denoted as region 2 and region 3 
on the diagram, should indicate the location of the 
NF1 gene. In fact, the panel shown in the figure can 
be used to divide the long arm of chromosome 17 into 
five regions. Mapping the genetic markers used for the 
rnultipoint analysis shown in Fig. 2 against this somatic 
cell hybrid panel gives consistent results, as shown in 
Fig. 4. This adds additional confidence to the genetic 
map, indicates that the hybrid mapping panel does not 
apparently contain major chromosome rearrangements. 
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and further supports the argument 
that the translocations contained in 
NF13 and DCR1 are causative of 
the disease, since they map to pre- 
cisely the right interval. This com- 
bination of approaches thus pro- 
vides very useful complementary 
information. 
Physical mapping 
The identification of a trans- 
location breakpoint is directly 
approachable using pulsed field gel 
electrophoresis (PFGE). What one 
requires is a probe that resides on 
a restriction fragment altered by the 
translocation. Since the rare-cutting 
restriction enzymes used in this 
sort of analysis often generate 
fragments of several hundred kilo- 
bases or more, the probe used 
does not have to be precisely at 
the translocation breakpoint in 
order to identify its presence. 
Preliminary efforts with the most 
closely linked genetic markers 
(HHH202, TH17.19 and EW206) 
did not, however, reveal any 
abnormalities in PFGE analysis of 
the two translocation patient 
DNAs 19. This analysis did, however, 
indicate that HHH202 and TH17.19 
lie only about a hundred kilobases 
apart (not surprising since TH17.19 
was cloned from a PFGE fragment 
detected by HHH202; Ref. 18), and 
also somewhat surprisingly that 
EW206 and EW207 can be no more 
than 700 kb apar09. This latter find- 
ing was unexpected given the 
approximate 4 cM genetic distance 
between these probes, which 
would have predicted a physical 
separation of about 4 million base 
pairs. This may indicate the 
possibility of a hot spot for recom- 
bination between these two 
probes, although the possibility of 
data errors or incorrect paternity 







Schematic diagram of the translocations 
identified in two remarkable patients 
with NF1. (A) t(1;17)(p34.3;qll.2). (B) 
t( 17;22)(ql 1.2;ql 1.2). Only the involved 
chromosomes are shown. Note that in 
both patients one breakpoint involves 
17q11.2, the precise location of NF1 by 
linkage analysis 
To identify the translocation breakpoints on physi- 
cal maps, several groups have now identified more 
DNA markers in this region of chromosome 17, and 
two groups have now identified markers capable of 
visualizing the translocation breakpoints by PFGE 
analysis. Wallace et al. prepared a series of chromo- 
some-17-specific NotI linking clones e0, and used the 
somatic cell hybrid mapping panel in Fig. 4 to identify 
clones in regions 2 and 3. One of their region 2 
clones, denoted 17L1, detects PFGE abnormalities in 
the t(1;17) patient and in her affected offspring e~. The 
presence of abnormal fragments with a variety of dif- 
ferent enzymes and in several different tissues pro- 
vides conclusive evidence that this 
translocation breakpoint maps near 
17L1, and was used to construct 
the physical map in Fig. 5. The 
t(17;22) breakpoint is slightly fur- 
ther away, as shown in the figure. 
Both these breakpoints are telo- 
meric to 17L1, since this probe is 
absent in the NF13 and DCR-1 
hybrids. 
O'Connell et al. 1~ mapped a 
large number of cosmids to regions 
2 and 3. One of these, denoted 
cll-lFlO, detects abnormal PFGE 
fragments with both translocation 
patients 22, and maps to region 3. Its 
approximate localization on the 
physical map is also shown in Fig. 
5. Thus these two cloned probes, 
which reside on the same 600 kb 
NruI fragment, bracket the two 
translocations. 
Future work 
The combination of genetic and 
physical mapping techniques has 
thus dramatically narrowed the 
potential localization of the NF1 
gene to a region of only a few 
hundred kilobases in band ql l .2  of 
chromosome 17. The fact that the 
two translocation breakpoints are 
separated by a minimum of 60 kb, 
based on the physical map in Fig. 
5, indicates that the NF1 gene is of 
at least moderate size. This sort of 
analysis does not, of course, place 
an upper limit on the size. In light 
of the very high spontaneous mu- 
tation rate, it is not impossible that 
the neurofibromatosis gene might 
be a 'megagene' analogous to the 
Duchenne muscular dystrophy 
gene, since that locus displays a 
similarly high mutation rate, pre- 
sumably because its 2000 kb tran- 
scription unit provides a broad tar- 
get for mutation. With this in mind, 
it is perhaps somewhat surprising 
that thus far no PFGE abnormalities 
have been identified in sporadic NF1 patients with the 
17L1 or 1FIO probes 21.ee. 
The presence of a strong CpG island between the 
two translocation breakpoints (Fig. 5) is an interesting 
feature, since such GC-rich hypomethylated islands 
often mark the 5' end of expressed genese3. It is 
somewhat difficult, however, to understand how both 
translocations could alter the expression of such a 
gene, since one of the translocation breakpoints would 
have to lie in the 5' flanking region at a considerable 
distance, The recent identification of a transcribed 
gene within a large intron of the factor VIII gene (1. 
Gitschier, pers. commun.) points out, however, 
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Mapping of DNA markers near NF1 with a panel of somatic cell hybrids 11.18,19. The 
portion of human chromosome 17 present in each hybrid is indicated by a black bar, 
SP-3 and P12.3B were derived from non-NF1 cell lines carrying chromosome 17 
translocations. DCR-1 is a hybrid carrying the der(1) chromosome from the t(1;17) 
NF1 patient whose chromosome rearrangement is shown in Fig. 3; NF13 carries the 
der(22) chromosome from the t(17;22) NF1 patient. 7AE-11 is a hybrid created using 
microcell-mediated transfer 1~, and has also been an important cloning resource, This 
set of hybrids can be used to subdivide the area around NF1 into five regions. A 
probe is then placed in an interval by Southern blot analysis with each member of 
the hybrid panel. Note that the derived order of markers agrees with the genetic 
map (Fig, 2). The NF1 gene is presumably located at the interface between regions 2 
and 3, at the breakpoints of DCR-1 and NF13. 
that the situation may be complex. Efforts are currently 
underway using chromosome jumping, chromosome 
walking, and selective cloning from specific PFGE 
fragments to identify additional DNA markers within 
the region of the translocations. It will be important to 
determine whether  these are simple translocations, 
or whether  loss of material has occurred, as oc- 
casionally has been found in such situations. The 
focus now shifts to an attempt to identify transcripts 
from within this region, using a combinat ion of 
'zoo blots' (Southern blots containing DNA from dif- 
ferent species, to assess sequence conservation), 
FIG [] c e n t r o m e r e  
Physical map of the region around 
the two NF1 translocation break- 
points. 17L1A is a subclone of the 
NotI linking clone 17L1 (Ref. 21) and 
cll-lF10 is a cosmid22; both detect 
abnormal pulsed field gel fragments 
in the NF1 translocation patient 
DNAs. Both probes are on the same M 
600 kb NruI fragment, and they [ // 
flank the translocations, the location ] H 1230 
o f  w h i c h  is indicated b y  crosshatch- 
ing. Sizes are in kilobases. Key: M, 






northern blots, and cDNA library 
screening. 
One of the potential difficulties 
in identifying the NF1 transcript is an 
uncertainty about its normal func- 
tion, or even its usual tissue of 
expression. The peripheral  neuro- 
fibromas which are such a character- 
istic feature of the disease are made 
up primarily of Schwann cells and 
fibroblasts, but analysis of clonality 
has indicated that these tumors are 
not clonal e~, implying that they may 
be reacting to some local stimulatory 
influence. While most of the features 
of the disease occur in the neural 
crest, transcript identification may 
turn out to be more difficuh than 
was the case for Duchenne muscular 
dystrophy or retinoblastoma. It is not 
clear, for example,  whether  the nor- 
real transcript or the abnormal tran- 
script, or both, will be expressed in 
neural crest-derived tissues. 
There are some features of NF1 
that suggest that the gene is a tumor 
suppressor  gene, analogous to the 
retinoblastoma or Wihns' tumor 
genes. In this model, the disease 
gene is actually recessive at the cell- 
ular level, although the inherited 
predisposit ion is dominant. This 
would be consistent with the fact 
that most cells of an affected individ- 
ual are apparent ly normal, with the enormous variable 
expressivity of the disease potentially arising from 
somatic genetic events required to produce actual cell- 
ular abnormalities. In such a model, the nonclonal 
benign neurofibromas would presumably be respond- 
ing to a clonal abnormality of a nearby cell or group 
of cells, or even to the nerve axon. 
A standard method of inferring the presence of 
such tumor suppressor  genes has been  the observation 
of allele losses at the affected locus in tumors from 
such individuals es. While benign neurofibromas are 
useless for such analyses in light of their nonclonality, 
t (1;17)  t (17;22)  
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several groups have analysed malignant tumors arising 
in NF1 patients, particularly neurofibrosarcomas, and 
have identified a high frequency of allele loss on 
chromosome 17. The fact that there is a known tumor 
suppressor gene (most likely the P53 gene 26) on 17p, 
however, makes this analysis quite complicated, as the 
reduction to homozygosity has in general involved the 
entire chromosome, and has occasionally even 
involved 17p but not 17q (B. Seizinger and T. Glover, 
unpublished). Thus, at present, there is no strong bio- 
logic evidence to support the tumor suppressor gene 
mechanism for NF1. 
Conclusion 
Analysis of NF1 has proceeded rapidly in the past 
two years, with localization of the gene now narrowed 
to only 0.01% of the genome. The availability of 
translocations has played a critical role in this process, 
and should now greatly assist the identification of a 
candidate transcript, which may well be possible in 
the next one to two years. The results are likely to 
shed important light on the biology of the neural crest, 
the mechanism of tumor formation, and the nature of 
this puzzling and dramatic disorder. 
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